#United States #Irvine #Tellus #ASAHI INTECC #Veloute

ASAHI INTECC Launches Veloute™ and Tellus™ Microcatheters in the U.S.

On September 8, 2025, ASAHI INTECC, a leading manufacturer of medical devices, announced the official launch of its innovative embolization microcatheters, Veloute™ and Tellus™, in the U.S. market. These advanced medical devices are engineered for use in angiography and the infusion of therapeutic agents, including embolization procedures, specifically within the peripheral vasculature.

Cutting-edge Design and Features

One of the standout features of the Veloute™ and Tellus™ microcatheters is their proprietary braid-reinforced shaft. This design element significantly enhances pushability while ensuring that the lumen remains patent during procedures. Each microcatheter is equipped with a radiopaque distal marker, allowing for clearer visualization and accurate positioning during complicated procedures. The Veloute™ model features a 1.7Fr tip, and the Tellus™ has a slightly larger 1.9Fr tip, both aimed at improving access in distal regions of blood vessels. Moreover, they include a flexible distal segment that can accommodate straight and angled shapes for navigating smaller and more tortuous vessels.

The design also incorporates a hydrophilic coating to facilitate smoother tracking and transitions, significantly benefiting interventional radiologists during procedures.

Proven Performance and Biocompatibility

Extensive bench testing has verified both devices meet rigorous performance criteria, including tensile strength, kink resistance, flow rate, burst pressure, slidability, and torque strength. Additionally, biocompatibility testing was conducted in accordance with ISO 10993 standards, confirming that the Veloute™ and Tellus™ microcatheters are non-cytotoxic, non-sensitizing, non-pyrogenic, non-hemolytic, and thromboresistant. This extensive assessment reassures clinicians of the devices' safety and efficacy in clinical applications.

Empowering Interventional Radiologists

Joe Wright, General Manager of ASAHI INTECC USA, expressed enthusiasm for the launch: "With Veloute and Tellus, we set out to give interventional radiologists the confidence to reach and treat. This launch showcases our rich heritage in catheter engineering aimed specifically at peripheral embolization, combining remarkable trackability and stability with the tactile control our physicians expect from ASAHI products."

Availability and Future Implications

The Veloute™ and Tellus™ microcatheters are now available for purchase, effective immediately across the U.S. medical market. Interventional radiologists and interested medical professionals can learn more about these products by visiting ASAHI INTECC USA's website or by contacting their local ASAHI representatives for product demonstrations.

About ASAHI INTECC

Founded in Japan, ASAHI INTECC Co., Ltd. specializes in manufacturing an array of medical devices, industrial materials, and innovative products. The company's hallmark is its unique wire processing technology, which positions ASAHI INTECC at the forefront of medical device innovation globally. Their operations extend across the U.S., Europe, Singapore, China, and Hong Kong, with headquarters situated in Seto, Japan. ASAHI INTECC USA, Inc. operates from Irvine, California, focusing on delivering cutting-edge medical solutions to healthcare professionals.

As the healthcare landscape continues to evolve, the introduction of Veloute™ and Tellus™ represents a significant leap in enhancing precision and control in vascular procedures, affirming ASAHI INTECC’s commitment to improving patient outcomes through technological innovation.